the importance of better selecting patients with cml who are eligible for treatment discontinuation
Published 1 year ago • 112 plays • Length 1:10Download video MP4
Download video MP3
Similar videos
-
2:23
factors to consider when selecting jak inhibitors for patients with mf
-
1:22
examples of challenging scenarios for tfr in cml & how to manage them
-
0:39
selecting patients with scd for allosct
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
4:03
discontinuing treatment and predicting relapse in cml
-
0:48
evolving treatment goals in cml
-
34:43
managing quality in the art laboratory
-
14:18
dr. khadar - cancer || dr. khadar vali
-
5:56
hematologic system examination
-
0:40
the impact of aca in cml & the importance of monitoring these patients
-
3:07
how age as a prognostic factor affects treatment options for all
-
2:45
continuity of care for patients with hematological predispositions to aml
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
2:41
an overview of the latest advances in hematology
-
1:00
the role of flot2 in cml progression & how it differs from aml
-
1:17
ponatinib versus ascimininib in the third-line treatment of cml
-
0:59
developing lsc-targeting agents in aml: progress and current therapeutic capacity
-
1:48
do all patients require maintenance therapy following allosct?
-
2:04
the importance of patient perspectives during treatment journeys
-
1:36
patient selection in the treatment of nhl